Tadalafil for the treatment of pulmonary arterial hypertension

Bibliography

• Barst RJ, Gibbs SR, Ghofrani HA, Updated evidence-based treatment algorithm in pulmonary arterial hypertension. JACC 2009;54:s78-84
   Google Scholar
• Badesch DB, . REVEAL registry data; summary of treatments at enrollment; personal communication; Presented PHA June 20, 2008; Houston, Texas, Pulmonary Hypertension Association's 8th International Conference
   Google Scholar
• Eisen SA, Miller DK, Woodward RS, The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990;150:1881-4
   PubMed Web of Science ®Google Scholar
• Iskedjian M, Einarson TR, MacKeigan LD, Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin Ther 2002;24:302-16
   PubMed Web of Science ®Google Scholar
• Galie N, Ghofrani HA, Torbicki A, Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-57
   PubMed Web of Science ®Google Scholar
• Forgue ST, Patterson BE, Bedding AW, Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol 2005;61:280-8
   Google Scholar
• Francis SH, Corbin JD. Cyclic GMP: synthesis, metabolism, and function. In: Murad P, editor, Advances in pharmacology. New York: Academic Press; 1994. p. 115-70
   Google Scholar
• Wrishko RE, Dingemanse J, Yu A, Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. J Clin Pharmacol 2008;48:610-18
   PubMed Web of Science ®Google Scholar
• Spence R, Mandagere A, Harrison B, No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers. J Pharm Sci 2009;98(12):4962-74
   Google Scholar
• Bendayan D, Shitrit D, Kramer MR. Combination with prostacyclin and tadalafil for severe pulmonary arterial hypertension: a pilot study. Respirology 2008;13:916-18
   PubMed Web of Science ®Google Scholar
• Schermuly RT, Kreisselmeier DP, Ghofrani HA, Chronic sildenafil treatment inhibits monocrotoline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med 2004;169:39-45
   PubMed Web of Science ®Google Scholar
• Pauvert O, Bonnet S, Rousseau E, Sildenafil alters calcium signaling and vascular tone in pulmonary artery from chronically hypoxic rats. Am J Physiol Lung Cell Mol Physiol 2004;287:577-83
   PubMed Web of Science ®Google Scholar
• Zhao L, Mason NA, Morrell NW, Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 2001;104:424-8
   PubMed Web of Science ®Google Scholar
• Tessier RB, Azdinello M, Fiori H, Tadalafil improves oxygenation in a model of newborn pulmonary hypertension. Pediatr Crit Care Med 2008;9:330-2
   PubMedGoogle Scholar
• Tsai BM, Turrentine MW, Sheridan BC, Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression. Ann Thorac Surg 2006;81:271-8
   Google Scholar
• Sastry BK, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 2004;43:1149-53
   PubMed Web of Science ®Google Scholar
• Karatza AA, Narang I, Rosenthal M, Treatment of primary pulmonary hypertension with oral sildenafil. Respiration 2004;71:192-4
   PubMedGoogle Scholar
• Michelakis ED, Tymchak W, Noga M, Long-term treatment woth oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003;108:2066-9
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Rose F, Schermuly RT, Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 2003;42:158-64
   PubMed Web of Science ®Google Scholar
• Stiebellehner L, Petkov V, Vonbank, Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension. Chest 2003;123:1293-5
   PubMed Web of Science ®Google Scholar
• Tay EL, Geok-Mui MK, Poh-Hoon MC, Yip J. Sustained benefit of tadalafil in patients with pulmonary arterial hypertension with prior response to sildenafil: a case of 12 patients. Int J Cardiol 2008;125:416-17
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Voswinckel R, Reichenberger F, Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol 2004;44:1488-96
   PubMed Web of Science ®Google Scholar
• Palmieri EA, Affuso F, Fazio S, Tadalafil in primary pulmonary arterial hypertension. Ann Intern Med 2004;141:743-4
   PubMed Web of Science ®Google Scholar
• Aggarwal P, Patial RK, Negi PC, Marwaha R. Oral tadalafil in pulmonary artery hypertension: a prospective study. Indian Heart J 2007;59:329-35
   PubMedGoogle Scholar
• Castro de Carvalho A, Hovnanian AL, Fernandes CJ, Tadalafil as treatment for idiopathic pulmonary arterial hypertension. Arq Bras Cardiol 2006;87:e195-7
   PubMedGoogle Scholar
• Affuso F, Palmieri EA, Di Conza P, Tadalafil improves quality of life and exercise tolerance in idiopathic pulmonary arterial hypertension. Int J Cardiol 2006;108:429-31
   PubMed Web of Science ®Google Scholar
• Bharani A, Patel A, Saraf J, Efficacy and safety of PDE-5 inhibitor tadalafil in pulmonary arterial hypertension. Indian Heart J 2007;59:323-8
   PubMedGoogle Scholar
• Galie N, Brundage BH, Ghofrani HA, Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009;119:2894-903
   PubMed Web of Science ®Google Scholar